Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.

Postgraduate medicine

Volumn 125, Issue 3, 2013, Pages 47-57

  Grimm, Michael ^a   Han, Jenny ^b   Weaver, Carole ^b   Griffin, Pete ^b   Schulteis, Christine T ^b   Dong, Haiying ^b   Malloy, Jaret ^b  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPID; PEPTIDE; VENOM;

ARTICLE; BLOOD; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME; VENOMS;

EID: 84882240639     PISSN: None     EISSN: 19419260     Source Type: None    
DOI: 10.3810/pgm.2013.05.2660     Document Type: Article

References (0)